Cited by 256Pulmonary Hypertension Research and TreatmentsVascular Anomalies and TreatmentsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 102 of the 104 references it cites were found in a registry or an index.

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Open access

Taichman, Darren B., Ornelas, Joe, Chung, Lorinda, Klinger, James R., Lewis, Sandra, Mandel, Jess, Palevsky, Harold I., Rich, Stuart, Sood, Namita, Rosenzweig, Erika B., Trow, Terence K., Yung, Rex, Elliott, C. Gregory, Badesch, David B.·2014·Chest

DOI 10.1378/chest.14-0793PMC PMC4137591

Open this paper in CoChat — free account Open PDF

Abstract

Objective Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. The objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence.Methods This guideline was based on systematic reviews of English language evidence published between 1990 and November 2013, identified using the MEDLINE and Cochrane Library databases. The strength of available evidence was graded using the Grades of Recommendations, Assessment, Development, and Evaluation methodology. Guideline recommendations, or consensus statements when available evidence was insufficient to support recommendations, were developed using a modified Delphi technique to achieve consensus.Results Available evidence is limited in its ability to support high-level recommendations. Therefore, we drafted consensus statements to address many clinical questions regarding pharmacotherapy for patients with PAH. A total of 79 recommendations or consensus statements were adopted and graded.Conclusions Clinical decisions regarding pharmacotherapy for PAH should be guided by high-level recommendations when sufficient evidence is available. Absent higher level evidence, consensus statements based upon available information must be used. Further studies are needed to address the gaps in available knowledge regarding optimal pharmacotherapy for PAH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1378/chest.14-0793

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness
Rosa, S. D., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,040
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359
Consensus methods: characteristics and guidelines for use
Fink, A., Kosecoff, J., Chassin, M., & Brook, R. H. (1984) · American Journal of Public Health · doi:10.2105/ajph.74.9.979 · Cited by 2,089
Inhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,784
Definitions and Diagnosis of Pulmonary Hypertension
Hoeper, M. M., Bogaard, H. J., Condliffe, R., Frantz, R. P., Khanna, D., Kurzyna, M., Langleben, D., Manes, A., Satoh, T., Torres, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.032 · Cited by 1,763
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,558
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
Channick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06250-x · Cited by 1,529
Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial
Simonneau, G., Barst, R. J., Galiè, N., Naeije, R., Rich, S., Bourge, R. C., KEOGH, A. M., Oudiz, R. J., Frost, A., Blackburn, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,440
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Адзерихо, И. Э., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H. A., Jansa, P., Jing, Z., Brun, F. L., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,439
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
Sitbon, O., Humbert, M. J. C., Nunès, H., Parent, F., Garcia, G., Hervé, P., Rainisio, M., & Simonneau, G. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02012-0 · Cited by 1,374
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,305
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
Sitbon, O., Humbert, M. J. C., Jaïs, X., Ioos, V., Hamid, A. M., Provencher, S., Garcia, G., Parent, F., Hervé, P., & Simonneau, G. (2005) · Circulation · doi:10.1161/circulationaha.104.488486 · Cited by 1,244
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220
Survival in Primary Pulmonary Hypertension
McLaughlin, V. V., Shillington, A. C., & Rich, S. (2002) · Circulation · doi:10.1161/01.cir.0000029100.82385.58 · Cited by 1,217
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096
Tadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,096
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
Galiè, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742510 · Cited by 1,077
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
Badesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00002 · Cited by 1,071
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
Galiè, N., Rubin, L., Hoeper, M. M., Jansa, P., Al‐Hiti, H., Meyer, G. M. B., Chiossi, E., Kusic‐Pajic, A., & Simonneau, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60919-8 · Cited by 917
Bosentan Therapy in Patients With Eisenmenger Syndrome
Galiè, N., Beghetti, M., Gatzoulis, M. Α., Granton, J. T., Berger, R. M. F., Lauer, A., Chiossi, E., & Landzberg, M. J. (2006) · Circulation · doi:10.1161/circulationaha.106.630715 · Cited by 844
Medical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · CHEST Journal · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 701
Outcome of Pulmonary Vascular Disease in Pregnancy: A Systematic Overview From 1978 Through 1996
Weiss, B. M., Zemp, L., Seifert, B., & Hess, O. M. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00162-4 · Cited by 670
Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension
McLaughlin, V. V., Genthner, D., Panella, M. M., & Rich, S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380501 · Cited by 660
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Humbert, M. J. C., Barst, R. J., Robbins, I. M., Channick, R. N., Galiè, N., Boonstra, A., Rubin, L. J., Horn, E. M., Manes, A., & Simonneau, G. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00028404 · Cited by 638
Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H., & Rubin, L. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-358oc · Cited by 624
Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension
Simonneau, G., Rubin, L. J., Galiè, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00004 · Cited by 613
Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
Jaeschke, R., Guyatt, G. H., Dellinger, P., Schunemann, H., Levy, M. M., Kunz, R., Norris, S., Bion, J., & for the GRADE working group (2008) · BMJ · doi:10.1136/bmj.a744 · Cited by 577
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
McLaughlin, V. V., Benza, R. L., Rubin, L. J., Channick, R. N., Voswinckel, R., Tapson, V. F., Robbins, I. M., Olschewski, H., Rubenfire, M., & Seeger, W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.027 · Cited by 564
Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin
Barst, R. J., Rubin, L. J., McGoon, M. D., Caldwell, E. J., Long, W. A., & Levy, P. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-6-199409150-00003 · Cited by 548
Pediatric Pulmonary Hypertension
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze‐Neick, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.028 · Cited by 543
Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects
Rosenzweig, E. B., Kerstein, D., & Barst, R. J. (1999) · Circulation · doi:10.1161/01.cir.99.14.1858 · Cited by 507
Medical Therapy for Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Simonneau, G., Rubin, L. J., & McLaughlin, V. V. (2007) · CHEST Journal · doi:10.1378/chest.06-2674 · Cited by 438
Littérature commentée
Jégo, P. (1996) · La Revue de Médecine Interne · doi:10.1016/0248-8663(96)83752-0 · Cited by 409
Primary pulmonary hypertension
Dresdale, D. T., Schultz, M., & Michtom, R. J. (1951) · The American Journal of Medicine · doi:10.1016/0002-9343(51)90020-4 · Cited by 399
Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension
Montani, D., Savale, L., Natali, D., Jaïs, X., Hervé, P., Garcia, G., Humbert, M. J. C., Simonneau, G., & Sitbon, O. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq170 · Cited by 360
Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Authors/Task Force Members:, Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J.-L., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr046 · Cited by 314
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.
Rubin, L. J., Groves, B. Μ., Reeves, J. Τ., Frosolono, M. F., Handel, F., & Cato, A. E. (1982) · Circulation · doi:10.1161/01.cir.66.2.334 · Cited by 312
Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol Infusion
Shapiro, S., Oudiz, R. J., Cao, T., Romano, M. A., Beckmann, X. J., Georgiou, D., Mandayam, S., Ginzton, L. E., & Brundage, B. H. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00187-3 · Cited by 302
Safety and Efficacy of IV Treprostinil for Pulmonary Arterial Hypertension
Tapson, V. F., Gomberg‐Maitland, M., McLaughlin, V. V., Benza, R. L., Widlitz, A. C., Krichman, A. D., & Barst, R. J. (2006) · CHEST Journal · doi:10.1378/chest.129.3.683 · Cited by 293
Treatment Goals of Pulmonary Hypertension
McLaughlin, V. V., Gaine, S., Howard, L., Leuchte, H. H., Mathier, M. A., Mehta, S., Palazzini, M., Park, M., Tapson, V. F., & Sitbon, O. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.034 · Cited by 293
Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension
Krowka, M. J., Frantz, R. P., McGoon, M. D., Severson, C. J., Plevak, D. J., & Wiesner, R. H. (1999) · Hepatology · doi:10.1002/hep.510300307 · Cited by 291
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era
Jaïs, X., Olsson, K. M., Barberà, J. A., Blanco, I., Torbicki, A., Peacock, A. J., Vizza, C. D., Macdonald, P. S., Humbert, M. J. C., & Hoeper, M. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00141211 · Cited by 265
Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Oudiz, R. J., Schilz, R. J., Barst, R. J., Galiè, N., Rich, S., Rubin, L. J., & Simonneau, G. (2004) · CHEST Journal · doi:10.1378/chest.126.2.420 · Cited by 263
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2012) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2011.10.006 · Cited by 257
Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension
Gomberg‐Maitland, M., Tapson, V. F., Benza, R. L., McLaughlin, V. V., Krichman, A. D., Widlitz, A. C., & Barst, R. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-766oc · Cited by 222
Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension
Lang, I. M., Gómez‐Sánchez, M. Á., Kneußl, M., Naeije, R., Escribano, P., Skoro‐Sajer, N., & Vachiéry, J. (2006) · CHEST Journal · doi:10.1378/chest.129.6.1636 · Cited by 202
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial
Hiremath, J., Thanikachalam, S., Parikh, K. H., Shanmugasundaram, S., Banġera, S., Shapiro, L., Pott, G. B., Vnencak‐Jones, C. L., Arneson, C. P., Wade, M., et al. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.09.005 · Cited by 197
Epoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary Hypertension
AGUILAR, R. V., & Farber, H. W. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.2004042 · Cited by 172
Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).
Jones, D. K., Higenbottam, T., & Wallwork, J. L. (1987) · Heart · doi:10.1136/hrt.57.3.270 · Cited by 164
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey
MEYER, S. E., McLaughlin, V. V., Seyfarth, H.-J., Bull, T. M., Vizza, C. D., Gomberg‐Maitland, M., Preston, I. R., Barberà, J. A., Hassoun, P. M., Halank, M., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00089212 · Cited by 160
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
Rubin, L. J., & Badesch, D. B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00009 · Cited by 149
Pulmonary hypertension and pregnancy: a series of eight cases
Smedstad, K. G., Cramb, R., & Morison, D. H. (1994) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03011545 · Cited by 149
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial (Annals of Internal Medicine (2008) 149, (521-530))
Simonneau, G., Rubin, L. J., Galiè, N., Barst, R. J., Fleming, T. R., & Frost, A. (2009) · Annals of Internal Medicine · Cited by 129
Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing
Atz, A. M., Adatia, I., Lock, J. E., & WESSEL, D. L. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00668-8 · Cited by 127
Correction
(2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.12.004 · Cited by 123
Pregnancy and Primary Pulmonary Hypertension
Stewart, R. W., TUAZON, D. M., Duarte, A. G., & Olson, G. (2001) · CHEST Journal · doi:10.1378/chest.119.3.973 · Cited by 120
Micrococcus-Associated Central Venous Catheter Infection in Patients With Pulmonary Arterial Hypertension
Oudiz, R. J., Widlitz, A. C., Beckmann, X. J., Camanga, D., Alfie, J., Brundage, B. H., & Barst, R. J. (2004) · CHEST Journal · doi:10.1378/chest.126.1.90 · Cited by 114
PRIMARY PULMONARY HYPERTENSION IN PREGNANCY
McCaffrey, R. M., & Dunn, L. J. (1964) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-196408000-00001 · Cited by 113
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
Benza, R. L., Seeger, W., McLaughlin, V. V., Channick, R. N., Voswinckel, R., Tapson, V. F., Robbins, I. M., Olschewski, H., & Rubin, L. J. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.08.019 · Cited by 108
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
Kemp, K., Savale, L., O’Callaghan, D. S., Jaïs, X., Montani, D., Humbert, M. J. C., Simonneau, G., & Sitbon, O. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.11.002 · Cited by 108
Primary pulmonary hypertension in pregnancy; a role for novel vasodilators
Monnery, L., Nanson, J., & Charlton, G. A. (2001) · British Journal of Anaesthesia · doi:10.1093/bja/87.2.295 · Cited by 98
Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease
Packer, M., Medina, N., & Yushak, M. (1984) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(84)80048-0 · Cited by 97
Comparative Acute Effects of Adenosine and Prostacyclin in Primary Pulmonary Hypertension
Nootens, M., Schrader, B. J., Kaufmann, E., Vestal, R. E., Long, W. A., & Rich, S. (1995) · CHEST Journal · doi:10.1378/chest.107.1.54 · Cited by 95
Wide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
Taichman, D. B., McGoon, M. D., Harhay, M. O., Archer-Chicko, C. L., Sager, J. S., Murugappan, M. N., Chakinali, M. M., Palevsky, H. I., & Gallop, R. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60747-7 · Cited by 93
Bloodstream Infections in Patients Given Treatment With Intravenous Prostanoids
Kallen, A. J., Lederman, E. R., Balaji, A. B., Trevino-Garrison, I., Petersen, E. E., Shoulson, R. L., Saiman, L. M., Horn, E. M., Gomberg‐Maitland, M., Barst, R. J., et al. (2008) · Infection Control and Hospital Epidemiology · doi:10.1086/529552 · Cited by 92
High dose titration of calcium channel blocking agents for primary pulmonary hypertension: Guidelines for short-term drug testing
Rich, S., & Kaufmann, E. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90556-o · Cited by 91
Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol
Badesch, D. B., McGoon, M. D., Barst, R. J., Tapson, V. F., Rubin, L. J., Wigley, F. M., Kral, K. M., Raphiou, I., & Crater, G. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081277 · Cited by 85
Evidence-Based Clinical Practice Guidelines Hypertension: Updated ACCP Medical Therapy for Pulmonary Arterial
McLaughlin, V. V., Badesch, D. B., Abman, S. H., Simonneau, G., & Rubin, L. J. (2007) · Cited by 85
Methodologies for the Development of CHEST Guidelines and Expert Panel Reports
Lewis, S. Z., Diekemper, R. L., Ornelas, J., & Casey, K. R. (2014) · CHEST Journal · doi:10.1378/chest.14-0824 · Cited by 80
Anaesthesia for caesarean section in the presence of severe primary pulmonary hypertension
OʼHare, R., McLoughlin, C., Milligan, K. R., McNamee, D., & Sidhu, H. (1998) · British Journal of Anaesthesia · doi:10.1093/bja/81.5.790 · Cited by 78
Cardiac problems in pregnancy
Colie, C. F. (1991) · Reproductive Toxicology · doi:10.1016/0890-6238(91)90025-b · Cited by 74
Pregnancy outcome in women with pulmonary arterial hypertension: single-center experience from India
Subbaiah, M., Kumar, S., Roy, K. K., Sharma, J. B., & Singh, N. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-2761-8 · Cited by 66
Effects of tolazoline hydrochloride (priscoline) on circulatory dynamics of patients with pulmonary hypertension
Rudolph, A. M., Paul, M. H., Sommer, L. S., & Nadas, A. S. (1958) · American Heart Journal · doi:10.1016/0002-8703(58)90059-0 · Cited by 65
Bloodstream Infections in Patients With Pulmonary Arterial Hypertension Treated With Intravenous Prostanoids: Insights From the REVEAL REGISTRY®
Kitterman, N., Poms, A. D., Miller, D. P., Lombardi, S., Farber, H. W., & Barst, R. J. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.05.014 · Cited by 64
Primary Pulmonary Hypertension and Pregnancy
Dawkins, K. D., Burke, C. M., Billingham, M. E., & Jamieson, S. W. (1986) · CHEST Journal · doi:10.1378/chest.89.3.383 · Cited by 63
Inhaled nitric oxide for primary pulmonary hypertension in pregnancy
Lam, G. K. W. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01549-6 · Cited by 60
Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension
Decoene, C., Bourzoufi, K., Moreau, D., Narducci, F., Crepin, F., & Krivosic-Horber, R. (2001) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03016836 · Cited by 58
The Effect of Diluent pH on Bloodstream Infection Rates in Patients Receiving IV Treprostinil for Pulmonary Arterial Hypertension
Rich, J. D., Glassner, C., Wade, M., Coslet, S., Arneson, C. P., Doran, A. K., & Gomberg‐Maitland, M. (2011) · CHEST Journal · doi:10.1378/chest.11-0245 · Cited by 58
Inhaled nitric oxide therapy in pregnancy complicated by pulmonary hypertension
Robinson, J. N., Banerjee, R., Landzberg, M. J., & Thiet, M.-P. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70686-1 · Cited by 50
IOM Sets Out “Gold Standard” Practices for Creating Guidelines, Systematic Reviews
Kuehn, B. M. (2011) · JAMA · doi:10.1001/jama.2011.597 · Cited by 49
Effects of Commercial Air Travel on Patients With Pulmonary Hypertension
Roubinian, N. H., Elliott, C. G., Barnett, C. F., Blanc, P. D., Chen, J. W., Marco, T. D., & Chen, H. (2012) · CHEST Journal · doi:10.1378/chest.11-2016 · Cited by 48
Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report.
Badalian, S. S., Silverman, R. K., Aubry, R. H., & Longo, J. (2000) · PubMed · Cited by 42
Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension
Olofsson, C., Bremme, K. A., Forssell, G., & Öhqvist, G. (2001) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2001.450220.x · Cited by 37
Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
(2007) · PubMed · Cited by 32
Pulmonary arterial hypertension in pregnant women
Safdar, Z. (2012) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465812461680 · Cited by 30
Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel
Burns, R. M., Peacock, A., Johnson, M., & Church, C. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.10.007 · Cited by 29
Primary pulmonary hypertenson in pregnancy: A case report
Kiss, H., Egarter, C., Asseryanis, E., Putz, D., & Kneußl, M. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90047-0 · Cited by 29
Alta incidencia de bacteriemia por bacilos gramnegativos en pacientes con hipertensión pulmonar tratados con treprostinil por vía intravenosa
López‐Medrano, F., Fernández‐Ruiz, M., Caño, M. J., Barrios, E., Vicente-Hernández, M., Aguado, J. M., & Subías, P. E. (2012) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2012.06.005 · Cited by 19
High Incidence of Bloodstream Infection Due to Gram-negative Bacilli in Patients With Pulmonary Hypertension Receiving Intravenous Treprostinil
López‐Medrano, F., Fernández‐Ruiz, M., Caño, M. J., Barrios, E., Vicente-Hernández, M., Aguado, J. M., & Escribano, P. (2012) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2012.09.008 · Cited by 18
Primary pulmonary hypertension and pregnancy.
Carro-Jiménez, E. J., & López, J. E. (2006) · PubMed · Cited by 13
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study
Simonneau, G., D’Armini, A. M., Ghofrani, H. A., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. D., Wang, C., Wilkins, M. R., Fritsch, A., et al. (2013) · CHEST Journal · doi:10.1378/chest.1783236 · Cited by 12
Has the 6-Min Walk Distance Run Its Course?
McLaughlin, V. V. (2012) · CHEST Journal · doi:10.1378/chest.12-1110 · Cited by 9

Flagged first, then by citations

2 of the 104 references couldn’t be matched to a known paper.

Sorted by citations

Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Pediatric Pulmonary Hypertension
Abman, S. H., Hansmann, G., Archer, S. L., Ivy, D. D., Adatia, I., Chung, W. K., Hanna, B. D., Rosenzweig, E. B., Raj, J. U., Cornfield, D. N., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000329 · Cited by 1,173
Update of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Pulmonary arterial hypertension: pathogenesis and clinical management
Thenappan, T., Ormiston, M. L., Ryan, J. J., & Archer, S. L. (2018) · BMJ · doi:10.1136/bmj.j5492 · Cited by 1,004
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676

See all 256

Authors: Taichman, D. B., Ornelas, J., Chung, L., Klinger, J. R., Lewis, S., Mandel, J., Palevsky, H. I., Rich, S., Sood, N., Rosenzweig, E. B., Trow, T. K., Yung, R., Elliott, C. G., & Badesch, D. B.
Affiliations: University of Pennsylvania (US)
American College of Chest Physicians (US)
VA Palo Alto Health Care System (US)
Brown University (US)
University of California San Diego (US)
University of Chicago (US)
The Ohio State University (US)
Columbia University Irving Medical Center (US)
Yale University (US)
Johns Hopkins University (US)
University of Utah (US)
University of Colorado Denver (US)
Corresponding author: Ornelas, Joe
ORCID: Taichman, Darren B.
Chung, Lorinda
Klinger, James R.
Lewis, Sandra
Mandel, Jess
Palevsky, Harold I.
Rich, Stuart
Sood, Namita
Rosenzweig, Erika B.
Elliott, C. Gregory
Venue: Chest
Publisher: Elsevier BV
Published: 2014-08
Volume: 146
Issue: 2
Pages: 449-475
ISSN: 0012-3692 (ISSN-L)
DOI: 10.1378/chest.14-0793
PMC: PMC4137591
OpenAlex: W2157947374
Cited by: 256
References: 104
Citations by year: 2026: 6 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 13 · 2021: 18 · 2020: 14 · 2019: 25 · 2018: 29 · 2017: 43 · 2016: 40 · 2015: 43 · 2014: 5
FWCI: 7.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: CHEST Journal (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: pulmonary arterial hypertension, pharmacotherapy, adult patients, antihypertensive drugs, consensus statement, treatment guidelines, level of evidence
MeSH terms: Adult, Antihypertensive Agents, Delphi Technique, Humans, Hypertension, Pulmonary, Practice Guidelines as Topic, Consensus, Familial Primary Pulmonary Hypertension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks